In Serving to Meet International Well being Challenges”

Fireplace Chat Being Held on Tuesday, Could 4th @ 10am Jap Time

JUPITER, Fla., April 22, 2021 (GLOBE NEWSWIRE) — Dyadic Worldwide, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Firm”) (NASDAQ:DYAI), a worldwide biotechnology firm targeted on creating and deploying its proprietary C1-cell protein manufacturing platform to optimize the event of vaccines, therapeutics and different protein based mostly merchandise at this time introduced that it’s going to host a hearth chat on Tuesday, Could 4, 2021 at 10:00am Jap Time. The hearth chat will concentrate on the potential of the transformative Dyadic C1 protein know-how in serving to meet world well being challenges.

The moderated dialogue will embody the next Key Opinion Leaders (KOLs):

  • Alain Townsend, Ph.D. – Weatherall Institute – Oxford College
  • Albert Osterhaus, P.V.M, Ph.D. – Erasmus Medical Centre
  • Cecil Nick – Parexel (Scientific & Regulatory Assist)
  • Joris Vandeputte – Worldwide Alliance for Organic Standardization

The dialogue will embody:

  • Regulatory concerns and benefits of the C1 platform
  • Case research describing the profitable manufacturing of excessive worth antigens for each Schmallenburg Virus and Rift Valley Fever Virus in relation to the efficiency in different manufacturing platforms
  • The efforts being undertaken by Dyadic to deal with the rising SARS-CoV-2 variants together with Dyadic’s improvement efforts advancing a SARS-CoV-2 receptor binding area (RBD) vaccine candidate – DYAI-100 plus the speedy engineering of C1 cell strains to specific recognized and rising variants
  • The C1 platform’s potential for creating and manufacturing multi-valent COVID-19 and different subunit vaccines, together with a pan-coronavirus vaccine that may shield towards most or all variants
  • Glycoengineering C1-cells to supply mAbs and different antibodies

The dialog might be moderated by Dr. David Bramhill, a veteran within the biotechnology trade with intensive expertise utilizing a big selection of protein manufacturing applied sciences together with E. coli, Saccharomyces cerevisiae, Pichia pastoris, Tetrahymena, Insect SF9 steady cells (not baculovirus), CHO, and HEK293.

You’re invited to affix this essential dialogue. You’ll study why Dyadic and a rising variety of key opinion leaders and material specialists consider that Dyadic’s C1 protein manufacturing platform presents a sturdy manufacturing resolution for the associated fee efficient versatile scale business manufacturing of therapeutics and vaccines.

You may register for the fireplace chat here.

Alain Townsend, Ph.D. is an Immunologist on the Weatherall Institute of Molecular Drugs, College of Oxford, who has been engaged on COVID-19 over the past yr.

Most of Dr. Townsend’s work has been involved with the presentation of Influenza antigens with class I molecules of the Main Histocompatibility advanced. Prior to now, he recognized the key targets for T cells because the conserved nucleoprotein and matrix protein parts of the virus and demonstrated {that a} system of cytosolic antigen presentation exists that passes peptides derived from these proteins into the ER the place they bind to class I MHC molecules. With the current pandemic, this curiosity continues with a sensible extension into the difficulty of whether or not heterotypic immunity (between pandemic strains) could be induced in man with dwell attenuated strains of influenza. We’ve got developed our personal design of dwell attenuated virus known as S-FLU, that depends on mutations within the haemagglutinin sign sequence which can be permissive for an infection however forestall replication of the virus. The benefit of this method is that all the viral proteins are expressed of their acceptable context within the lung, and thus can induce a full set of native T and B cell responses. Dr. Townsend is creating strategies to ship the vaccine virus by aerosol in collaboration with Ronan Mac Loughlin at Aerogen. Preliminary leads to collaboration with Dr. Kanta Subbarao (NIH) present that our vaccine viruses are able to stopping sickness brought on by probably the most virulent types of influenza in a murine and ferret an infection mannequin, and we’re learning responses within the pig as a related giant animal (in collaboration with Elma Tchillian, Pirbright). Dr. Townsend is presently investigating the mechanisms of this immunity within the pig.

Albert Osterhaus, P.V.M, Ph.D. has been Head of the Division of Viroscience at Erasmus MC Rotterdam till 2014, is at present Director of the Heart of An infection Drugs and Zoonosis Analysis and Visitor-Professor on the College of Veterinary Drugs Hannover. He has a protracted observe file as a scientific researcher and Principal Investigator of quite a few main scientific initiatives. At Erasmus MC, Professor Osterhaus has run a diagnostic virology lab with greater than 40 employees and a analysis virology lab with over 150 personnel. His analysis programme follows a novel built-in “viroscience” idea, bringing collectively world-leading scientists in molecular virology, immunology, epidemiology, pathogenesis, and intervention research on human and animal virus infections. Among the many main accomplishments are the invention of greater than 70 new viruses of people and animals (e.g. human metapneumovirus, coronaviruses, influenza viruses), elucidation of the pathogenesis of main human and animal virus infections, and improvement of novel intervention methods.

The worldwide recognition of Professor Osterhaus is additional highlighted by main prizes, visitor lecture invites, (co-)organiserships of worldwide conferences and editorships of scientific journals. Professor Osterhaus has acted as mentor for greater than 80 PhD college students and holds a number of key patents. He’s additionally the creator of greater than 1300 papers in peer-reviewed journals, collectively cited greater than 70,000 occasions, and his H index is > 116. At present he is also Chair of the European Working Group on Influenza (ESWI). He organised quite a few worldwide scientific conferences on influenza and different rising infections, holds a number of senior editorships and obtained quite a few prestigious awards. He’s member of the Dutch and German Nationwide Academies of Sciences, member of the Belgium Academia of Drugs, and Commander of the Order of the Dutch Lion.

Cecil Nick, Vice President (Technical), at PAREXEL Consulting has been working in regulatory affairs and scientific improvement for over 30 years; for over 25 years he has targeted on organic medicines. Mr. Nick has explicit experience in monoclonals and biosimilars, having labored on over 20 such applications, engaged in over 50 interactions and conferences with regulatory companies within the EU, US, Canada, Australia, Mexico, Brazil and supported 6 submissions within the EU and US. He has additionally participated extensively in Business and Worldwide conferences on the topic. Moreover, Mr. Nick has intensive expertise in orphan medication and in quite a few therapeutic areas together with, however not restricted to, oncology, inflammatory illness, diabetes, progress and hematology.

Mr. Nick is a Fellow of TOPRA and has been a visitor lecture at Cardiff College MSc in Scientific Analysis and Greenwich College MSc in Pharmaceutical Sciences programs and Biotech Module chief for the TOPRA MSc course. He was on the editorial panel of SCRIP Scientific Analysis and has authored many articles on regulatory and scientific improvement points.

Dr. Joris Vandeputte, President of IABS (Worldwide Alliance for Organic Standardization), is a founding member of IABS-EU, the European affiliate of IABS. Since 1955, IABS is the worldwide unbiased platform, the place stakeholders meet for change on science and points associated to vaccines, cell and gene remedy and human Biotherapeutics. IABS stimulates consensus constructing that finally leads to regulatory frameworks and proposals to resolution makers. In December 2019, IABS and VAC2VAC organised the convention Animal testing for vaccines – Implementing Alternative, Discount and Refinement: Challenges and Priorities Bangkok, Thailand, December 3-4, 2019

Dr. Vandeputte acquired his Physician’s diploma in Veterinary Drugs in 1976 at Gent College, College of Veterinary Drugs, Belgium. As a virologist at this College (1976-1980), Joris found H1N1 flu as a pathogen for swine, resulting in a greater understanding of H1N1 as a zoonosis. Subsequently, on the Belgian Ministry of Agriculture, he labored on animal illness management in Belgium and the European Union earlier than becoming a member of Institut Mérieux, Rhône Mérieux, which turned Merial. Dr. Vandeputtehas greater than 35 years science, trade and worldwide organisation’s expertise. He has been concerned within the full worth chain of vaccines: analysis, improvement, and manufacturing, regulatory and advertising and marketing.

About C1 Protein Manufacturing Platform

The C1 protein manufacturing platform presents a big alternative to leverage an industrial protein manufacturing know-how to transcend the boundaries of legacy protein manufacturing applied sciences enabling giant scale manufacturing of therapeutics and vaccines. Within the new regular of world vaccination the world wants a flexible and dependable protein manufacturing know-how that gives speedy response and strong, price efficient manufacturing. Since 2016, Dyadic has been busy re-engineering the C1 protein manufacturing platform to supply recombinant glycoprotein based mostly vaccines & therapeutics for human and animal well being functions.

About Dyadic Worldwide, Inc.

Dyadic Worldwide, Inc. is a worldwide biotechnology firm which is creating what it believes might be a doubtlessly important biopharmaceutical gene expression platform based mostly on the fungus Thermothelomyces heterothallica (previously Myceliophthora thermophila), named C1. The C1 microorganism, which allows the event and large-scale manufacture of low-cost proteins, has the potential to be additional developed right into a protected and environment friendly expression system that will assist velocity up the event, decrease manufacturing prices and enhance the efficiency of biologic vaccines and medicines at versatile business scales. Dyadic is utilizing the C1 know-how and different applied sciences to conduct analysis, improvement and business actions for the event and manufacturing of human and animal vaccines and medicines, akin to virus like particles (VLPs) and antigens, monoclonal antibodies, Fab antibody fragments, Fc-Fusion proteins, biosimilars and/or biobetters, and different therapeutic proteins. Sure different analysis actions are ongoing which embody the exploration of utilizing C1 to develop and produce sure metabolites and different biologic merchandise. Dyadic pursues analysis and improvement collaborations, licensing preparations and different business alternatives with its companions and collaborators to leverage the worth and advantages of those applied sciences in improvement and manufacture of biopharmaceuticals. Because the growing older inhabitants grows in developed and undeveloped nations, Dyadic believes the C1 know-how might assist deliver biologic vaccines, medication, and different biologic merchandise to market sooner, in higher volumes, at decrease price, and with new properties to drug builders and producers, and enhance entry and price to sufferers and the healthcare system, however most significantly save lives.

Please go to Dyadic’s web site at http://www.dyadic.com for added info, together with particulars concerning Dyadic’s plans for its biopharmaceutical enterprise.

Secure Harbor Relating to Ahead-Trying Statements

This press launch comprises forward-looking statements inside the which means of Part 27A of the Securities Act of 1933 and Part 21E of the Securities Change Act of 1934, together with these concerning Dyadic Worldwide’s expectations, intentions, methods, and beliefs pertaining to future occasions or future monetary efficiency. Precise occasions or outcomes might differ materially from these within the forward-looking statements due to varied essential elements, together with these described within the Firm’s most up-to-date filings with the SEC. Dyadic assumes no obligation to replace publicly any such forward-looking statements, whether or not due to new info, future occasions or in any other case. For a extra full description of the dangers that might trigger our precise outcomes to vary from our present expectations, please see the part entitled “Threat Components” in Dyadic’s annual experiences on Type 10-Ok and quarterly experiences on Type 10-Q filed with the SEC, as such elements could also be up to date infrequently in Dyadic’s periodic filings with the SEC, that are accessible on the SEC’s web site and at http://www.dyadic.com.

Contact:

Dyadic Worldwide, Inc.
Ping W. Rawson
Chief Monetary Officer
Telephone: (561) 743-8333
Electronic mail: [email protected]

 

LEAVE A REPLY

Please enter your comment!
Please enter your name here